🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Faldaprevir placebo

Found 17 matching trials

Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)

PHASE2

The objective was to investigate the antiviral effect, safety, and pharmaco...

Status

Completed

Location

1220.5.0001 Boehringer Ingelheim Investigational Site

Start Date

2008-10

Trial ID

NCT00774397

Treatments Being Tested

BI 201335 NA 240 mg QD / LI PegIFN/RBV BI 201335 NA 120mg QD / LI PegIFN/RBV BI 201335 NA 240 mg QD PegIFN/RBV BI 201335 NA 240 mg QD PegIFN/RBV BI 201335 NA 240 mg BID PegIFN/RBV PegIFN/RBV BI 201335 NA 240 mg QD PegIFN/RBV Placebo

Safety, Tolerability, and Pharmacokinetics of BI 201335 NA in Healthy Male Subjects

PHASE1

The objective of this trial was to investigate safety, tolerability, and ph...

Status

Completed

Location

Multiple Locations

Start Date

2008-04

Trial ID

NCT02182297

Treatments Being Tested

BI 201335 NA in single rising doses Placebo

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients

PHASE2

The current Standard of Care (SOC) for chronic HCV infection, which is pegy...

Status

Completed

Location

1220.14.003 Boehringer Ingelheim Investigational Site

Start Date

2009-07

Trial ID

NCT00947349

Treatments Being Tested

ribavirin (RBV)pegylated interferon (PegIFN) alfa-2a pegylated interferon (PegIFN) alfa-2a ribavirin (RBV)BI 201335 NA low placebo pegylated interferon (PegIFN) alfa-2a ribavirin (RBV)BI 201335 NA high BI 201335 NA low BI 201335 NA high placebo BI 201335 NA high Placebo

Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of BI 201335 NA and Bioavailability in Healthy Male Subjects

PHASE1

The objective of this study was to investigate the safety, tolerability, an...

Status

Completed

Location

Multiple Locations

Start Date

2006-09

Trial ID

NCT02182323

Treatments Being Tested

BI 201335 NA Placebo solution

IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1

PHASE3

The aim of the study is to confirm efficacy of treatment for 16 and 24 week...

Status

Completed

Location

1241.20.00026 Boehringer Ingelheim Investigational Site

Start Date

2012-12

Trial ID

NCT01732796

Treatments Being Tested

Ribavirin (RBV)BI 201335 (Faldaprevir)Ribavirin (RBV)BI 207127 BI 201335 (Faldaprevir)Ribavirin (RBV)BI 207127 Faldaprevir (BI 201335)BI 207127

Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Subjects.

PHASE1

The objective of this study is to evaluate the effect of multiple doses of ...

Status

Completed

Location

1241.40.1 Boehringer Ingelheim Investigational Site

Start Date

2013-10

Trial ID

NCT01965431

Treatments Being Tested

BI 207127 BI 207127 placebo Faldaprevir placebo Faldaprevir Moxifloxacin (Avalox®)

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)

PHASE3

The objective of this trial is to evaluate the efficacy and safety of two d...

Status

Completed

Location

1220.47.0004 Boehringer Ingelheim Investigational Site

Start Date

2011-04

Trial ID

NCT01297270

Treatments Being Tested

BI201335 PegIFN/RBV BI201335 Placebo

A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C Infection

PHASE3

The objectives of this study are: 1. To evaluate the efficacy and safety o...

Status

Withdrawn

Location

Multiple Locations

Start Date

2012-09

Trial ID

NCT01608737

Treatments Being Tested

PegIFN/RBV BI 201335 BI 201335 PegIFN/RBV BI 201335

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

PHASE3

The aim of this trial is to evaluate the efficacy and the safety of BI 2013...

Status

Completed

Location

1220.7.0091 Boehringer Ingelheim Investigational Site

Start Date

2011-06

Trial ID

NCT01358864

Treatments Being Tested

BI 201335 Pegylated Interferon-alpha (IFN)Ribavirin (RBV)Placebo

Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced

PHASE1

This study will investigate safety, antiviral activity, and pharmacokinetic...

Status

Completed

Location

1220.2.10 Boehringer Ingelheim Investigational Site

Start Date

2007-09

Trial ID

NCT00793793

Treatments Being Tested

BI201335 BI201335 BI201335 BI201335 Placebo

Previous Next